Identification of Gα12-vs-Gα13-coupling determinants and development of a Gα12/13-coupled designer GPCR

Manae Tatsumi,Christian Cruz,Nozomi Kamakura,Riku Kuwabara,Gaku Nakamura,Tatsuya Ikuta,Ravinder Abrol,Asuka Inoue
DOI: https://doi.org/10.1038/s41598-024-61506-4
IF: 4.6
2024-05-16
Scientific Reports
Abstract:G-protein-coupled receptors (GPCRs) transduce diverse signals into the cell by coupling to one or several Gα subtypes. Of the 16 Gα subtypes in human cells, Gα 12 and Gα 13 belong to the G 12 subfamily and are reported to be functionally different. Notably, certain GPCRs display selective coupling to either Gα 12 or Gα 13 , highlighting their significance in various cellular contexts. However, the structural basis underlying this selectivity remains unclear. Here, using a Gα 12 -coupled designer receptor exclusively activated by designer drugs (DREADD; G 12 D) as a model system, we identified residues in the α5 helix and the receptor that collaboratively determine Gα 12 -vs-Gα 13 selectivity. Residue-swapping experiments showed that G 12 D distinguishes differences between Gα 12 and Gα 13 in the positions G.H5.09 and G.H5.23 in the α5 helix. Molecular dynamics simulations observed that I378 G.H5.23 in Gα 12 interacts with N103 2.39 , S169 3.53 and Y176 34.53 in G 12 D, while H364 G.H5.09 in Gα 12 interact with Q264 5.71 in G 12 D. Screening of mutations at these positions in G 12 D identified G 12 D mutants that enhanced coupling with Gα 12 and to an even greater extent with Gα 13 . Combined mutations, most notably the dual Y176 34.53 H and Q264 5.71 R mutant, further enhanced Gα 12 / 13 coupling, thereby serving as a potential Gα 12/13 -DREADD. Such novel Gα 12/13 -DREADD may be useful in future efforts to develop drugs that target Gα 12/13 signaling as well as to identify their therapeutic indications.
multidisciplinary sciences
What problem does this paper attempt to address?